TY  - THES
A1  - Gross, Franziska
T1  - Verstärkung von Tumor Treating Fields durch Inhibition der MPS1 Kinase in Glioblastom-Zelllinien
T1  - Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by MPS1 inhibition
N2  - Tumor Treating Fields (TTFields) sind alternierende Wechselfelder mit einer intermediären Frequenz und niedrigen Intensität, die zu einer Destabilisierung des Spindelapparates während der Mitose führen. Sie sind als zusätzliche Behandlungsoption bei Glioblastoma multiforme zugelassen. Der mitotische Spindelkontrollpunkt überwacht eine fehlerhafte Anheftung der Spindelfasern von Schwesterchromatiden und leitet Reparaturprozesse ein. Monopolar spindle 1 (MPS1) ist eine Schlüsselkomponente dieses Kontrollpunktes und kann den durch TTFields physikalisch induzierten Spindelschäden entgegenwirken. Durch Zellzahlmessung, Zellzyklusuntersuchungen und durchflusszytometrische Analysen als auch Fluoreszenzfärbungen konnte gezeigt werden, dass eine Inhibition von MPS1 die antimitotischen Wirkungen von TTFields verstärken kann.
N2  - Tumor Treating Fields (TTFields) are alternating electric fields with low intensity and intermediate frequency approved for the therapy of glioblastoma multiforme.  TTFields therapy interrupts the spindle formation through mitosis leading to misalignment of chromosomes. Spindle assembly checkpoint (SAC) and its key component monopolar spindle 1 (MPS1) regulate proper chromosomal arrangement and segregation.  Here, we show that through the combination of physically interfering spindle formation by TTFields and chemical inhibition of MPS1, TTFields effects can be augmented promising a new target for multimodal treatment in glioblastoma therapy.
KW  - Tumortherapiefelder
KW  - Glioblastom
KW  - Mitose
KW  - Apoptosis
KW  - Aneuploidie
KW  - Spindle assembly checkpoint
KW  - Monopolar spindle 1
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-211804
ER  - 
TY  - JOUR
A1  - Egenolf, Nadine
A1  - Altenschildesche, Caren Meyer zu
A1  - Kreß, Luisa
A1  - Eggermann, Katja
A1  - Namer, Barbara
A1  - Gross, Franziska
A1  - Klitsch, Alexander
A1  - Malzacher, Tobias
A1  - Kampik, Daniel
A1  - Malik, Rayaz A.
A1  - Kurth, Ingo
A1  - Sommer, Claudia
A1  - Üçeyler, Nurcan
T1  - Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study
JF  - Therapeutic Advances in Neurological Disorders
N2  - Background and aims:
Small fiber neuropathy (SFN) is increasingly suspected in patients with pain of uncertain origin, and making the diagnosis remains a challenge lacking a diagnostic gold standard.
	
Methods:
In this case–control study, we prospectively recruited 86 patients with a medical history and clinical phenotype suggestive of SFN. Patients underwent neurological examination, quantitative sensory testing (QST), and distal and proximal skin punch biopsy, and were tested for pain-associated gene loci. Fifty-five of these patients additionally underwent pain-related evoked potentials (PREP), corneal confocal microscopy (CCM), and a quantitative sudomotor axon reflex test (QSART).
	
	
Results:
Abnormal distal intraepidermal nerve fiber density (IENFD) (60/86, 70%) and neurological examination (53/86, 62%) most frequently reflected small fiber disease. Adding CCM and/or PREP further increased the number of patients with small fiber impairment to 47/55 (85%). Genetic testing revealed potentially pathogenic gene variants in 14/86 (16%) index patients. QST, QSART, and proximal IENFD were of lower impact.
	
Conclusion:
We propose to diagnose SFN primarily based on the results of neurological examination and distal IENFD, with more detailed phenotyping in specialized centers.
KW  - algorithm
KW  - diagnosis
KW  - neurological examination
KW  - skin punch biopsy
KW  - small fiber neuropathy
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232019
SN  - 1756-2864
VL  - 14
ER  -